Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa
NCT06468228Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 44
01
Overview
A Phase 3 trial of lutikizumab in hidradenitis suppurativa (HS), sponsored by AbbVie Inc.. Started Jun 2024; status: active, not recruiting.
02
Drugs
lutikizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT06468228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06468228.